Extracellular matrix compositions with bactericidal or bacteriostatic characteristics useful for protecting and treating patients with bacterial infections

Patent metadata

Field	Value
Publication number	US-2018280574-A1
Application number	US-201815935707-A
Country	US
Kind code	A1
Filing date	Mar 26, 2018
Priority date	Mar 31, 2017
Publication date	Oct 4, 2018
Grant date	—

Abstract

Described is a formulation and method for reducing and treating bacterial infections in humans and animals with digested or non-digested extracellular matrix materials derived from non-epithelial and epithelial tissues.

First claim

We claim:

1 . A method for the treatment of a respiratory infection in a patient, comprising:
administering to the patient via an airway an effective dose of a non-cross-linked, micronized powder obtained from a devitalized native extracellular matrix material and processed at room temperature, said devitalized native extracellular matrix (ECM) selected from the group consisting of non-epithelial tissue, UBM, SIS, and UBS.

2 . The method of claim 1 wherein said micronized powder is non-enzymatically treated.

3 . The method of claim 1 wherein said micronized powder is stored at room temperature for at least two months.

4 . The method of claim 1 wherein said micronized powder is stored at room temperature for at least six months.

5 . The method of claim 1 wherein the infection is selected from the group of bacteria consisting of Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae.

6 . The method of claim 1 wherein said infection is localized at least to the lung.

7 . The method of claim 1 wherein said airway is trachea.

8 . The method of claim 1 wherein said administering route is intra-tracheal or intra-nasal.

9 . The method of claim 1 wherein said administering route is via inhalation.

10 . The method of claim 1 wherein said administering is via a spray.

11 . The method of claim 1 wherein the extracellular matrix material comprises urinary bladder matrix (UBM).

12 . The method of claim 1 wherein the extracellular matrix material comprises UBS.

13 . The method of claim 1 wherein said treatment comprises lavaging the airways of the patient with the micronized particle in a buffer solution.

14 . A composition, comprising:
a reconstituted material in a buffer solution comprising digested, micronized powder obtained from a devitalized extracellular matrix material including epithelial basement membrane, said reconstituted material comprising one or more native components of the extracellular matrix.

15 . The composition of claim 14 wherein the micronized powder is non-cross-linked.

16 . A method for reducing bacterial biofilm formation in a patient infected with the bacteria, comprising:
administering to said patient a micronized, devitalized extracellular matrix of an epithelial tissue comprising bactericidal activity against one or more bacteria selected from the group consisting of MSSA-, MSRA- Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa.

17 . The method of claim 16 wherein the micronized powder is non-cross-linked.

18 . A method for protecting a mammal from a bacterial-induced infection, comprising:
providing a reconstituted material comprising a micronized powder in a buffer solution obtained from a devitalized extracellular matrix material of an epithelial tissue, said reconstituted material comprising one or more native components of the extracellular matrix; and administering said material in a therapeutically effective dose by a route selected from the group consisting of intra-tracheal instillation, intra-nasal instillation-inhalation, spray, topical application, and combinations thereof.

19 . The method of claim 18 wherein the micronized powder is non-cross-linked.

Assignees

• Acell Inc
• Univ Pittsburgh

Inventors

• Gilbert Thomas Wayne
• Di Yuanpu

Classifications

• A61K9/0043

  Nose · CPC title

• A61L2430/40

  Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking · CPC title

• A61L27/54

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61K9/0075

  for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles · CPC title